ClearPoint Neuro (Nasdaq:CLPT) announced today that it entered into a multi-year license agreement with UCB over gene therapy delivery.
Solana Beach, California-based ClearPoint Neuro develops a therapy-enabling platform providing navigation and delivery to the brain. The licensing agreement with UCB establishes a partnership on delivery platforms for UCB’s gene therapy portfolio.
“We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on innovating through the adoption of next-generation science and new technologies,” said Jeremy Stigall, EVP and GM of biologics and drug delivery. “Over the past year, we have invested heavily in expanding our biologics and drug delivery team, as well as our product and services portfolio to attract partners of UCB’s caliber. UCB sought comprehensive tools to empower a seamless transition from benchtop testing to commercial success, and that’s precisely what our team can deliver today.”
Under the terms of the deal, UCB utilizes ClearPoint Neuro’s proprietary technology and services. It does this in connection with the development and commercialization of its gene therapy products.
Throughout the partnership, ClearPoint Neuro receives success-based milestone payments, too. The companies declined to disclose further financial details of their agreement.
“We look forward to the ClearPoint Neuro collaboration as we work on advancing UCB’s research and development pipeline in gene therapy. We believe that ClearPoint Neuro are a strong strategic fit for UCB as they are a company dedicated to innovation in the neurology space with a unique portfolio of navigation and drug delivery tools,” said Dhaval Patel, UCB EVP and chief science officer.
